Direzione e uffici C.I.B.

Direzione CIB:
Prof. Claudio Schneider
Email: claudio.schneider@Lncib.it

Segreteria CIB:
Prof. Roberto Gambari
Email: roberto.gambari@unife.it

SEGRETERIA ORGANIZZATIVA:
Elisabetta Lambertini
Tel: 0532/974451
Fax: 0532/974484
E-mail: lmblbt@unife.it

AMMINISTRAZIONE:
Vanessa Florit
Area di Ricerca
Padriciano, 99 - 34012 Trieste
Tel: 040/398979
Fax: 040/398990
E-mail: cib@lncib.it

Posta certificata C.I.B.:
cib@poste-certificate.it

Login



Piva Roberta Stampa
RESPONSABILE DELLA U. O.

Cognome e Nome Piva Roberta
Qualifica Professore Associato
Facoltà Medicina e Chirurgia
Dipartimento Biochimica e Biologia Molecolare
Settore Scientifico Disciplinare BIO10
E-mail Questo indirizzo e-mail è protetto dallo spam bot. Abilita Javascript per vederlo.

PERSONALE STRUTTURATO

Cognome e Nome Bianchi Nicoletta
Qualifica tecnico
Dipartimento Biochimica e Biologia Molecolare
Ente di appartenenza
Università degli Studi di Ferrara
Cognome e Nome Penolazzi Letizia
Qualifica Tecnico di laboratorio
Dipartimento Biochimica e Biologia Molecolare
Ente di appartenenza
Università degli Studi di Ferrara
Cognome e Nome Roberta Piva
Qualifica
PA
Dipartimento Biochimica e Biologia Molecolare
Ente di appartenenza
Università degli Studi di Ferrara
Cognome e Nome
Spisani Susanna
Qualifica
PA
Dipartimento Biochimica e Biologia Molecolare
Ente di appartenenza
Università degli Studi di Ferrara
Cognome e Nome
Qualifica
Dipartimento
Ente di appartenenza
Cognome e Nome
Qualifica
Dipartimento
Ente di appartenenza

PERSONALE NON STRUTTURATO

Cognome e Nome Franceschetti Tiziana
Qualifica Borsista
Dipartimento Biochimica e Biologia Molecolare
Ente di appartenenza
Università degli Studi di Ferrara
Cognome e Nome Lambertini Elisabetta
Qualifica Borsista
Dipartimento Biochimica e Biologia Molecolare
Ente di appartenenza
Università degli Studi di Ferrara
Cognome e Nome Torreggiani Elena
Qualifica Dottoranda
Dipartimento Biochimica e Biologia Molecolare
Ente di appartenenza
Università degli Studi di Ferrara
Cognome e Nome Vecchiatini Renata
Qualifica Dottoranda
Dipartimento Dipartimento di Discipline Medico-Chirurgiche della Comunicazione e del Comportamento
Ente di appartenenza
Università degli Studi di Ferrara
Cognome e Nome Vecchiatini Renata
Qualifica Dottoranda
Dipartimento Dipartimento di Discipline Medico-Chirurgiche della Comunicazione e del Comportamento
Ente di appartenenza
Università degli Studi di Ferrara
Cognome e Nome
Qualifica
Dipartimento
Ente di appartenenza

LINEE DI RICERCA

1. Analysis of the regulation of human Estrogen Receptor alpha gene expression. The transcriptional regulation of human ERa gene is very complex and only in part known. We are interested in the understanding the role of specific promoter regions of this gene in osteoblasts and osteoclasts Our previous results indicate that: - Runx2 is a regulator of ERa gene expression in osteoblasts: it binds specific cis elements of F promoter of ERa gene, “in vivo”, with opposite effects. - ERa and c-jun, c-fos and ATF-2, but not Fra-2 AP-1 factors interact “in vivo” with specific estrogen-responsive regulatory sequences and AP-1 cis-elements within the F promoter of the human ERa gene in osteoblast-like SaOS-2 cells. This recruitment is oscillatory and is modulated by 17-b-estradiol. This research is based on the employment of EMSA, ChIP, promoter analysis, mutagenesis, quantitative RT-PCR. This study includes also the employment of the “decoy” strategy. The transcription factor (TF) decoy technology involves synthetic double-stranded ODN containing a cis element with high affinity for a target TF and able to bind the TF after transfection into target cells. This attenuates the authentic cis-trans interactions leading to removal of the TF from the endogenous cis elements with subsequent specific modulation of gene expression. Therefore, the decoy approach is a powerful tool to modulate transcription of a target gene and directly study the transcriptional control of a gene of interest. The aim is the improvement of bone matrix deposition and the induction of osteoclast apoptosis. In order to obtain reproducible results we are investigating the better experimental approach in terms of cellular transfection, delivery system and source of primary cells.

2.Wnt signaling and estrogen signaling in bone. The major signaling pathways controlling bone formation and remodeling are those mediated by the following molecules: WNT, Lef1/Tcf, Runx2, AP-1, NFATc1 and Estrogen Receptor alpha. Increasing evidence suggests that all these factors may play a critical role both in osteoblasts and in osteoclasts, acting on different molecular target and associating with themselves. Our field of interest concerns the study of molecular mechanisms supporting the convergence of the above mentioned regulatory signals that may control bone-specific gene expression. The aim of this research is the employment of specific pharmacological molecules or nucleic acids-based drugs able to selectively modulate these pathways in human primary osteoblasts obtained from osteoporotic bones. This research program addresses also the analysis of new compounds present in unexplored plant extracts in terms of their ability to induce osteoclast apoptosis and osteoblast differentiation interfering with Wnt signaling and estrogen signaling. Different plant extracts are tested on primary cultures and modulation of apoptosis, cell proliferation, citotoxicity, EMSA interference, mineralization and osteoblast markers expression are evaluated.

3. Bone tissue regeneration through interaction between human primary osteoblasts and their mesenchymal precursors and biomaterials. The research program on bone tissue regeneration, is addressed to the development of an experimental model based on the combination of biomaterials, bone primary cells and their precursors. The knowledge resulted from molecular study will be employed to improve the performance of the cells combined with different biomaterials. In particular, we are interested in analyzing dental implant surfaces to optimize bone growth at the interface.

4. Analysis of expression and function of Slug gene in human normal osteoblasts and their mesenchymal precursors. In order to identify new potential osteoblast-specific proteins, we are investigating the role of Slug as mediator of Wnt signaling in relation to the expression profile of bone-related genes during human osteoblast differentiation.


TECNOLOGIE IN POSSESSO DELL'U. O.

  • Chromatin Immunoprecipitation (ChIP)
  • Transcription factor decoy (TFD)
  • Human osteoblasts primary cultures
  • Human osteoclasts primary cultures
  • Footprinting “in vivo”
  • Quantitative real time RT-PCR
  • Immunocytochemistry
  • siRNA methodologies
  • Reporter gene assays

STRUMENTAZIONE

Denominazione
Struttura ove la strumentazione è allocata
Responsabile della strumentazione
Real-Time PCR / TaqMan®ABI Prism 7700
Dip. Biochimica e Biologia Molecolare
Roberta Piva
Synthecon Rotary Cell Culture System
Dip. Biochimica e Biologia Molecolare
Roberta Piva

PUBBLICAZIONI

1. Penolazzi L, Lambertini E, Aguiari G, del Senno L, Piva R. Cis element 'decoy' against the upstream promoter of the human estrogen receptor gene. Biochim Biophys Acta. 2000 Jul 24;1492(2-3):560-7.
2. Lambertini E, Penolazzi L, Aguiari G, del Senno L, Pezzetti F, Sollazzo V, Piva R. Osteoblastic differentiation induced by transcription factor decoy against estrogen receptor alpha gene. Biochem Biophys Res Commun. 2002 Apr 5;292(3):761-70.
3. Lambertini E, Penolazzi L, Sollazzo V, Pezzetti F, de Mattei M, del Senno L, Traina GC, Piva R. Modulation of gene expression in human osteoblasts by targeting a distal promoter region of human estrogen receptor-alpha gene.J Endocrinol. 2002 Mar;172(3):683-93.
4. Selvatici R, Falzarano S, Traniello S, Pagani Zecchini G, Spisani S. Formylpeptides trigger selective molecular pathways that are required in the physiological functions of human neutrophils. Cell Signal. 2003 Apr;15(4):377-83.
5. Borgatti M, Lampronti I, Romanelli A, Pedone C, Saviano M, Bianchi N, Mischiati C, Gambari R. Transcription factor decoy molecules based on a peptide nucleic acid (PNA)-DNA chimera mimicking Sp1 binding sites. J Biol Chem. 2003 Feb 28;278(9):7500-9.
6. Lambertini E, Penolazzi L, Giordano S, Del Senno L, Piva R. Expression of the human oestrogen receptor-alpha gene is regulated by promoter F in MG-63 osteoblastic cells. Biochem J. 2003 Jun 15;372(Pt 3):831-9.
8. Penolazzi L, Lambertini E, Giordano S, Sollazzo V, Traina G, del Senno L, Piva R. Methylation analysis of the promoter F of estrogen receptor alpha gene: effects on the level of transcription on human osteoblastic cells. J Steroid Biochem Mol Biol. 2004 Jun;91(1-2):1-9.
9. Lambertini E, Penolazzi L, Magaldi S, Giordano S, del Senno L, Piva R. Transcription factor decoy against promoter C of estrogen receptor alpha gene induces a functional ER alpha protein in breast cancer cells. Breast Cancer Res Treat. 2005 Jul;92(2):125-32.
10. Piva R, Penolazzi L, Lambertini E, Giordano S, Gambari R. Induction of apoptosis of human primary osteoclasts treated with a transcription factor decoy mimicking a promoter region of estrogen receptor alpha. Apoptosis. 2005 Oct;10(5):1079-94.
11. Penolazzi L, Magri E, Lambertini E, Bianchini E, Piva R, Gambari R. "In vivo" local transfection of a cis element decoy mimicking an estrogen receptor alpha gene promoter region induces apoptosis of osteoclasts following application of orthodontic forces to rat teeth". Apoptosis 11, 1653-1656, 2006.
12. LAMBERTINI E., PENOLAZZI L., TAVANTI E., SCHINCAGLIA G.P., ZENNARO M., GAMBARI R., PIVA R. Human estrogen receptor alpha gene is a target of Runx2 transcription factor in osteoblasts. Experimental Cell Research, 313:1548-1560, 2007. 13. PENOLAZZI L., ZENNARO M., LAMBERTINI E., TAVANTI E., TORREGGIANI E., GAMBARI R, PIVA R. Induction of ER{alpha}Expression with Decoy Oligonucleotide Targeted to NFATc1 Binding Sites in Osteoblasts. Molecular Pharmacology, 71:1457-62, 2007. 14. FARABEGOLI F., BARBI C., LAMBERTINI E., PIVA R. Epigallocatechin-3-gallate downregulates estrogen receptor alpha function in MCF-7 breast carcinoma cells. Cancer Detection and Prevention, 31:499-504, 2007. 15. PENOLAZZI L., LAMBERTINI E., TAVANTI E., TORREGGIANI E., VESCE F., GAMBARI R., PIVA R. Evaluation of chemokine and cytokine profiles in osteoblast progenitors from umbilical cord blood stem cells by BIO-PLEX technology. Cell Biology International, 32:320-325, 2008 16.BIANCHINI C., CIORBA A., PELUCCHI S., PIVA R., PASTORE A. Head and Neck cancer: the possible role of stem cells. European Archives of Oto-Rhino-Laryngology and Head & Neck, 265:17–20, 2008. 17. LAMBERTINI E., TAVANTI E., TORREGGIANI E., PENOLAZZI L., GAMBARI R., PIVA R. ERa and AP-1 interact in vivo with a specific sequence of F promoter of human ERa gene in osteoblasts. Journal of Cellular Physiology, 216:101-110, 2008. 18. BIANCHINI C., PASTORE A., PELUCCHI S., TORREGGIANI E., LAMBERTINI E., MARCHESI E., MAGRI E., FRASSON C., QUERZOLI P., PIVA R. Sex hormones receptors levels in laryngeal carcinoma: a comparison between protein and RNA valuations. European Archives of Oto-Rhino-Laryngology and Head & Neck, 265:1089-1094, 2008. 19. PENOLAZZI L., POCATERRA B., TAVANTI E., LAMBERTINI E., VESCE F., GAMBARI R., PIVA R. Human osteoclasts from umbilical cord blood precursors are less prone to apoptotic stimuli than osteoclasts from peripheral blood. Apoptosis, 13:553-561, 2008. 20. PENOLAZZI L., LAMPRONTI I., BORGATTI M., KHAN M.T., ZENNARO M., PIVA R., GAMBARI R. Induction of apoptosis of human primary osteoclasts treated with extracts from the medicinal plant Emblica officinalis. BMC Complement Altern. Med. 8:59-69, 2008. 21. LISIGNOLI G., CODELUPPI K., TODOERTI K., MANFERDINI C., PIACENTINI A., ZINI N., GRASSI F., CATTINI L., PIVA R., RIZZOLI V., FACCHINI A., GIULIANI N., NERI A. Gene array profile identifies collagen type xv as a novel human osteoblast-secreted matrix protein. Journal of Cellular Physiology, 2009 in press. 22. BERGAMINI P., MARCHESI E., PAGNONI A., LAMBERTINI E., FRANCESCHETTI T., PENOLAZZI L., PIVA R. Synthesis, characterization of strontium –bile acid salts and their bioactivity vs. the anti-osteoporosis drug strontium ranelate. Journal of Inorganic Biochemistry, 2009 in press
LAMBERTINI E., TAVANTI E., TORREGGIANI E., PENOLAZZI L., GAMBARI R., PIVA R. ERa and AP-1 interact in vivo with a specific sequence of F promoter of human ERa gene in osteoblasts. Journal of Cellular Physiology, 216:101-110, 2008.


DOTTORATI DI RICERCA

Componente U.O. Dottorato di Ricerca Coordinatore Sede
Roberta Piva
Farmacologia e Oncologia Molecolare
Prof. Pier Andrea Borea
Dip. Medicina Clinica e Sperimentale
Spisani Susanna
Farmacologia e Oncologia Molecolare
Prof. Pier Andrea Borea
Dip. Medicina Clinica e Sperimentale

CONGRESSI C.I.B.

Congressi Partecipazione
CNB4

CNB5

CNB6

CNB7

CNB8

CNB9
CNB10